The meeting in autumn 1990 marks a clear change in the development of the contacts between Merck and RP as regards methylglucamine, into a formal and structured arrangement with clear agreement concerning prices and market shares allocation. This is confirmed by corroborated statements from both Aventis and Merck (see section 3.5).
Recital 68, Decision_act (EU) 2004/104
In forcesince 27 Nov 2002